Drug intelligence / Profile preview

KG008

Development stage: Preclinical
Lead developer: Kaigene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

KG008 is a bispecific antibody drug candidate developed by Kaigene, Inc. It is currently in preclinical development for the treatment of autoimmune diseases, which fall under the broader category of immune system diseases. As a bispecific antibody, KG008 is designed to simultaneously bind two different targets or epitopes, potentially offering enhanced therapeutic effects in modulating immune responses associated with autoimmune conditions. Specific molecular targets and detailed mechanisms of action have not been disclosed publicly as of June 2025[1][7].

Other names: KG008(Kaigene)

Beyond the preview

Go deeper on KG008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KG008.

Explore the full profile